T. Reinert

C. Andersen, K. Birkenkamp-Demtröder, S. Shchegrova, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Analysis of molecular intra-patient variation and delineation of a prognostic 12-gene signature in non-muscle invasive bladder cancer; technology transfer from microarrays to PCR

T. Ørntoft, N. Malats, F. Real, 2012, British Journal of Cancer.

Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery

H. Nielsen, T. Ørntoft, J. S. Pedersen, 2015, Gut.

A high resolution genomic portrait of bladder cancer: correlation between genomic aberrations and the DNA damage response

T. Ørntoft, C. Pan, J. Bartek, 2013, Oncogene.

Comparing single‐target and multitarget approaches for postoperative circulating tumour DNA detection in stage II–III colorectal cancer patients

C. Andersen, T. Reinert, M. Rasmussen, 2022, Molecular oncology.

Expression of MAGE-A3, NY-ESO-1, LAGE-1 and PRAME in urothelial carcinoma

T. Ørntoft, K. Zieger, M. Borre, 2012, British Journal of Cancer.

Clinical Implications of Monitoring Circulating Tumor DNA in Patients with Colorectal Cancer

H. Nielsen, T. Ørntoft, C. Andersen, 2017, Clinical Cancer Research.

Multicenter validation of cyclin D1, MCM7, TRIM29, and UBE2C as prognostic protein markers in non-muscle-invasive bladder cancer.

Per-Uno Malmström, Chin-Chen Pan, Michael Borre, 2013, The American journal of pathology.

Combinations of urinary biomarkers for surveillance of patients with incident nonmuscle invasive bladder cancer: the European FP7 UROMOL project.

E. Zwarthoff, L. Dyrskjøt, T. Reinert, 2013, The Journal of urology.

Circulating tumor DNA analysis for assessment of recurrence risk, benefit of adjuvant therapy, and early relapse detection after treatment in colorectal cancer patients.

C. Andersen, H. Sethi, T. Reinert, 2021 .

Plasma-only ctDNA-Guided MRD Detection in Patients with CRC—Letter

C. Andersen, T. Reinert, B. Zimmermann, 2021, Clinical Cancer Research.

Abstract 4801: Comprehensive genome methylation analysis in bladder cancer; identification and validation of novel methylated genes and application of these as urinary tumor markers

T. Ørntoft, C. Wiuf, L. Hansen, 2011 .

Serial circulating tumor DNA analysis to assess recurrence risk, benefit of adjuvant therapy, growth rate and early relapse detection in stage III colorectal cancer patients.

C. Andersen, H. Sethi, T. Reinert, 2021 .

Serial circulating tumor DNA analysis for detection of residual disease, assessment of adjuvant therapy efficacy and for early recurrence detection in colorectal cancer.

C. Andersen, S. Shchegrova, H. Sethi, 2018, Annals of Oncology.

Circulating tumor DNA to detect minimal residual disease, response to adjuvant therapy, and identify patients at high risk of recurrence in patients with stage I-III CRC.

C. Andersen, S. Shchegrova, H. Sethi, 2020 .

Combinations of urinary biomarkers for surveillance of patients with incident nonmuscle invasive bladder cancer: the European FP7 UROMOL project.

E. Zwarthoff, L. Dyrskjøt, T. Reinert, 2013, Journal of Urology.

Unraveling the potential clinical utility of circulating tumor DNA detection in colorectal cancer - evaluation in a nationwide Danish cohort.

T. Reinert, C. Demuth, J. Nors, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.

Error Characterization and Statistical Modeling Improves Circulating Tumor DNA Detection by Droplet Digital PCR.

J. S. Pedersen, C. Andersen, T. Reinert, 2022, Clinical chemistry.

Genomic alterations associated with resistance and circulating tumor DNA dynamics for early detection of progression on CDK4/6 inhibitor in advanced breast cancer.

J. Staaf, T. Reinert, A. R. Kodahl, 2024, International journal of cancer.